Please assess the completion status of the following clinical trial:

Trial Title: Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 18 to 64 years on the day of vaccination.~* Informed consent form signed and dated.~* Able to attend all scheduled visits and to comply with all trial procedures.~* For women of child bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 4 weeks after vaccination.~Exclusion Criteria :~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.~* For a woman of child-bearing potential: known pregnancy or positive serum/urine pregnancy test.~* Breast-feeding woman.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the four weeks preceding the trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy~* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.~* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures.~* Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.~* Receipt of any vaccination in the 4 weeks preceding the trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following the trial vaccination.~* Previous vaccination against influenza in the past 6 months with the trial vaccine or another vaccine.~* Thrombocytopenia or bleeding disorder in the 3 weeks preceding inclusion.~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Neoplastic disease or any hematologic malignancy, (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, and subjects who have a history of neoplastic disease and who have been disease free for \>=5 years).~* Personal or family history of Guillain-Barré Syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Fluzone Intradermal Vaccine Lot 1 (Type: EXPERIMENTAL): Participants will receive a dose of Influenza intradermal vaccine Lot 1
- Fluzone Intradermal Vaccine Lot 2 (Type: EXPERIMENTAL): Participants will receive a dose of Influenza intradermal vaccine Lot 2
- Fluzone Intradermal Vaccine Lot 3 (Type: EXPERIMENTAL): Participants will receive a dose of Influenza intradermal vaccine Lot 3
- Fluzone Intramuscular Vaccine (Type: ACTIVE_COMPARATOR): Participants will receive a dose of influenza intramuscular vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete